Shares of Ardelyx Inc. (ARDX) plunged 14.07% during Thursday's trading session, as the biopharmaceutical company reported disappointing financial results for the fourth quarter.
The company, which develops innovative therapies for cardiorenal diseases, failed to meet analysts' expectations for revenue and earnings. While Ardelyx managed to generate some revenue from its recently launched product, it was not enough to offset the significant research and development costs associated with its pipeline.
Analysts had anticipated Ardelyx would report progress on its lead drug candidate for chronic kidney disease, but the company provided little update on the clinical trials, raising concerns about potential delays or setbacks in the development program.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.